Aspirin-free strategy versus standard term dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
Restricted accessResearch articleFirst published online 2020
Aspirin-free strategy versus standard term dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
MehtaSRYusufSPetersRJ, et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial I.
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001;
358: 527–533.
2.
LevineGNBatesERBittlJA, et al.2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention, 2011 ACCF/AHA Guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery.Circulation2016;
134: e123–e155.
3.
ValgimigliMBuenoHByrneRA, et al.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J2018;
39: 213–260.
4.
VranckxPValgimigliMJuniP, et al.; GLOBAL LEADERS Investigators.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet2018;
392: 940–949.
5.
HahnJYSongYBOhJH, et al.; SMART-CHOICE Investigators.Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE Randomized Clinical Trial. JAMA2019;
321: 2428–2437.
6.
WatanabeHDomeiTMorimotoT, et al.; STOPDAPT-2 Investigators.
Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 Randomized Clinical Trial. JAMA2019;
321: 2414–2427.
7.
MehranRBaberUSharmaSK, et al.Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med2019;
381: 2032–2042.
8.
ArmstrongPCDhanjiARTuckerAT, et al.Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost2010;
8: 613–615.
9.
CimminielloCDondiLPedriniA, et al.Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: data from a large database in a community setting. Eur J Prev Cardiol2019;
26: 836–846.
10.
KhanSUShahzeb KhanMKaluskiE, et al.Compliance with the prescription of recommended medical therapy in trials comparing six versus 12 months or longer dual antiplatelet therapy: a systematic review and meta-analysis. Eur J Prev Cardiol2019;
26: 1673–1676.
